ANDA 70289, held by Chartwell RX. Tolazamide.
As of Nov 21, 2026, ANDA 70289 (Tolazamide), held by Chartwell RX, was first approved by FDA on Mar 13, 1986, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tolazamide250MG · tablet;oral | Tolazamide | Discontinued |
| May 9, 2001 | Supplement 13Manufacturing | Approved | None posted |
| Apr 3, 1996 | Supplement 12Manufacturing | Approved | None posted |
| Oct 24, 1995 | Supplement 11Manufacturing | Approved | None posted |
| Jul 24, 1992 | Supplement 9Labeling | Approved | None posted |
| Mar 14, 1990 | Supplement 8Manufacturing | Approved | None posted |
| May 9, 1989 | Supplement 7Labeling | Approved | None posted |
| Nov 8, 1988 | Supplement 6Manufacturing | Approved | None posted |
| Apr 4, 1988 | Supplement 1Manufacturing | Approved | None posted |
| Dec 22, 1987 | Supplement 4Manufacturing | Approved | None posted |
| Dec 22, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Dec 22, 1987 | Supplement 2Manufacturing | Approved | None posted |
| Mar 13, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters